Cost-Effectiveness of Gefitinib for First-Line Treatment of Advanced Non- Small Cell Lung Cancer: A Markov Model-Based Analysis

流行病學所LIU, PANG-HSIANGPANG-HSIANGLIUHU, FU-CHANGFU-CHANGHUWANG, JUNG-DERJUNG-DERWANG2018-06-292018-06-292008http://ntur.lib.ntu.edu.tw//handle/246246/173164[SDGs]SDG3Cost-Effectiveness of Gefitinib for First-Line Treatment of Advanced Non- Small Cell Lung Cancer: A Markov Model-Based Analysisconference paper